Camurus
Camurus AB, a pioneering biopharmaceutical company headquartered in Sweden, focuses on developing innovative medicines for patients with severe and chronic conditions. Founded in 2016, Camurus has rapidly established itself in the pharmaceutical industry, particularly in the fields of pain management and addiction treatment. The company is renowned for its proprietary FluidCrystal® technology, which enables the formulation of long-acting injectable therapies. This unique approach enhances patient compliance and treatment outcomes. Camurus has achieved significant milestones, including the successful launch of its lead product, Buvidal®, for opioid dependence, positioning itself as a leader in the market. With a strong presence in Europe and expanding operations globally, Camurus continues to make strides in improving patient care through its advanced therapeutic solutions.
DitchCarbon Score
How does Camurus's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Camurus's score of 41 is higher than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Camurus's reported carbon emissions
In 2023, Camurus reported total carbon emissions of approximately 561,800 kg CO2e. This figure includes Scope 1 emissions of about 158,900 kg CO2e, primarily from mobile combustion, and Scope 2 emissions of approximately 11,680 kg CO2e. The company’s Scope 3 emissions were significant, totalling around 385,600 kg CO2e, with downstream transportation and distribution accounting for the largest share at about 287,714 kg CO2e. Comparatively, in 2022, Camurus's total emissions were approximately 231,600 kg CO2e, with Scope 1 emissions at about 162,400 kg CO2e and Scope 2 emissions at approximately 16,690 kg CO2e. Scope 3 emissions for that year were around 60,300 kg CO2e, all attributed to fuel and energy-related activities. Despite the detailed emissions reporting, Camurus has not set specific reduction targets or climate pledges, indicating a potential area for future commitment. The company is headquartered in Sweden (SE) and operates within the pharmaceutical industry, which is increasingly focused on sustainability and reducing carbon footprints.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 162,400 | 000,000 |
| Scope 2 | 8,990 | 00,000 |
| Scope 3 | 60,300 | 000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Camurus is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
